发明名称 Mn/Ca Ix/Ca9 and Renal Cancer Prognosis
摘要 Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene expression product in a sample from the affected subject, wherein if 50% or fewer cells are found to express the MN/CA9 gene, then the subject is considered to have a poorer prognosis. MN/CA9 gene expression products useful in the prognostic methods include MN protein, MN polypeptide and/or MN nucleic acids. The methods are useful as an aid in the selection of treatment for a patient with renal cell carcinoma, alone or in combination with conventional tumor stage and/or grade information. The methods of the invention can be used, for example, to identify those patients requiring more aggressive therapy regimens, or those patients most likely to respond to adjuvant immunotherapies, particularly MN/CA IX/CA9-targeted therapies.
申请公布号 US2007224606(A1) 申请公布日期 2007.09.27
申请号 US20050578744 申请日期 2005.05.04
申请人 BAYER HEALTHCARE 发明人 SOYUPAK BULENT;ERDOGAN SEYDA
分类号 C12Q1/68;G01N33/574 主分类号 C12Q1/68
代理机构 代理人
主权项
地址